Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03799874 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)
A Phase 2 study of Acute Respiratory Distress Syndrome, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 7
- Study locations
NCT03799874 is a Phase 2 study of Acute Respiratory Distress Syndrome that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 32 participants, below the 366-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (91% lower). The trial reports 7 study locations across 4 states.
The verdict
NCT03799874, a Phase 2 study of Acute Respiratory Distress Syndrome, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will be a multi-center, prospective, randomized, partially double-blind, placebo-controlled Phase II clinical trial of inhaled CO (iCO) for the treatment of ARDS. The trial will be conducted at 7 tertiary care medical centers including Weill Cornell Medicine/NewYork-Presbyterian Hospital, Brigham and Women's Hospital (BWH), Massachusetts General Hospital (MGH), Duke University Hospital, Durham Veterans Administration Medical Center, New York-Presbyterian Brooklyn Methodist Hospital, and Duke Regional Hospital. The purpose of this study is to evaluate the safety, tolerability, and efficacy of inhaled carbon monoxide (iCO) for the treatment of ARDS and to examine the biologic readouts of low dose iCO therapy in patients with ARDS
Conditions Studied
Interventions
- OTHER Inhaled Medical air
- DRUG Inhaled Carbon Monoxide at 200 ppm
Study Locations (7)
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
New York
- New York-Presbyterian Brooklyn Methodist Hospital - Brooklyn
- Weill Cornell Medical College - New York
North Carolina
- Duke Regional Hospital - Durham
- Duke University Hospital - Durham
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2026-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03799874
The ClinicalTrials.gov registry entry for NCT03799874 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 366-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (91% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Respiratory Distress Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Inhaled Medical air is the first listed.
NCT03799874 reports 7 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03799874 about?
NCT03799874 is a clinical study titled "Safety and Efficacy Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)". This study will be a multi-center, prospective, randomized, partially double-blind, placebo-controlled Phase II clinical trial of inhaled CO (iCO) for the treatment of ARDS. The trial will be conducted at 7 tertiary care medical centers including Weill Cornell Medicine/NewYork-Presbyterian Hospital,...
What is the current status of trial NCT03799874?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2019-07-01. Estimated completion is 2026-01.
What conditions does trial NCT03799874 study?
This clinical trial studies the following conditions: Acute Respiratory Distress Syndrome.
What interventions are being tested in trial NCT03799874?
The interventions under investigation include: Inhaled Medical air (OTHER), Inhaled Carbon Monoxide at 200 ppm (DRUG).
Who is sponsoring clinical trial NCT03799874?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03799874 being conducted?
This trial has 7 study locations across Massachusetts, Missouri, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Respiratory Distress Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
RECRUITING · Phase 2
-
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
RECRUITING · Phase 2
-
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
RECRUITING · Phase 2
-
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.